Financial Statements

Enanta Pharmaceuticals, Inc. (ENTA)

$41.87

-2.14 (-4.86%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) 12816411745-
Net Income -79-36467218
Stock Dividends ---028
Dividend Paid -----
Retained Earnings 4912816411745

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 161188-
Annual Depreciation -468311
Capital Expenditure -1-1-5-3-3
Net PPE 11161188

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -251-293-549-339-307
Intangible and Goodwill -----

Enanta Pharmaceuticals, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Enanta Pharmaceuticals, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.